Cargando…

Engineered immunological niches to monitor disease activity and treatment efficacy in relapsing multiple sclerosis

Relapses in multiple sclerosis can result in irreversible nervous system tissue injury. If these events could be detected early, targeted immunotherapy could potentially slow disease progression. We describe the use of engineered biomaterial-based immunological niches amenable to biopsy to provide i...

Descripción completa

Detalles Bibliográficos
Autores principales: Morris, Aaron H., Hughes, Kevin R., Oakes, Robert S., Cai, Michelle M., Miller, Stephen D., Irani, David N., Shea, Lonnie D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398910/
https://www.ncbi.nlm.nih.gov/pubmed/32747712
http://dx.doi.org/10.1038/s41467-020-17629-z
_version_ 1783566039956586496
author Morris, Aaron H.
Hughes, Kevin R.
Oakes, Robert S.
Cai, Michelle M.
Miller, Stephen D.
Irani, David N.
Shea, Lonnie D.
author_facet Morris, Aaron H.
Hughes, Kevin R.
Oakes, Robert S.
Cai, Michelle M.
Miller, Stephen D.
Irani, David N.
Shea, Lonnie D.
author_sort Morris, Aaron H.
collection PubMed
description Relapses in multiple sclerosis can result in irreversible nervous system tissue injury. If these events could be detected early, targeted immunotherapy could potentially slow disease progression. We describe the use of engineered biomaterial-based immunological niches amenable to biopsy to provide insights into the phenotype of innate immune cells that control disease activity in a mouse model of multiple sclerosis. Differential gene expression in cells from these niches allow monitoring of disease dynamics and gauging the effectiveness of treatment. A proactive treatment regimen, given in response to signal within the niche but before symptoms appeared, substantially reduced disease. This technology offers a new approach to monitor organ-specific autoimmunity, and represents a platform to analyze immune dysfunction within otherwise inaccessible target tissues.
format Online
Article
Text
id pubmed-7398910
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-73989102020-08-13 Engineered immunological niches to monitor disease activity and treatment efficacy in relapsing multiple sclerosis Morris, Aaron H. Hughes, Kevin R. Oakes, Robert S. Cai, Michelle M. Miller, Stephen D. Irani, David N. Shea, Lonnie D. Nat Commun Article Relapses in multiple sclerosis can result in irreversible nervous system tissue injury. If these events could be detected early, targeted immunotherapy could potentially slow disease progression. We describe the use of engineered biomaterial-based immunological niches amenable to biopsy to provide insights into the phenotype of innate immune cells that control disease activity in a mouse model of multiple sclerosis. Differential gene expression in cells from these niches allow monitoring of disease dynamics and gauging the effectiveness of treatment. A proactive treatment regimen, given in response to signal within the niche but before symptoms appeared, substantially reduced disease. This technology offers a new approach to monitor organ-specific autoimmunity, and represents a platform to analyze immune dysfunction within otherwise inaccessible target tissues. Nature Publishing Group UK 2020-08-03 /pmc/articles/PMC7398910/ /pubmed/32747712 http://dx.doi.org/10.1038/s41467-020-17629-z Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Morris, Aaron H.
Hughes, Kevin R.
Oakes, Robert S.
Cai, Michelle M.
Miller, Stephen D.
Irani, David N.
Shea, Lonnie D.
Engineered immunological niches to monitor disease activity and treatment efficacy in relapsing multiple sclerosis
title Engineered immunological niches to monitor disease activity and treatment efficacy in relapsing multiple sclerosis
title_full Engineered immunological niches to monitor disease activity and treatment efficacy in relapsing multiple sclerosis
title_fullStr Engineered immunological niches to monitor disease activity and treatment efficacy in relapsing multiple sclerosis
title_full_unstemmed Engineered immunological niches to monitor disease activity and treatment efficacy in relapsing multiple sclerosis
title_short Engineered immunological niches to monitor disease activity and treatment efficacy in relapsing multiple sclerosis
title_sort engineered immunological niches to monitor disease activity and treatment efficacy in relapsing multiple sclerosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398910/
https://www.ncbi.nlm.nih.gov/pubmed/32747712
http://dx.doi.org/10.1038/s41467-020-17629-z
work_keys_str_mv AT morrisaaronh engineeredimmunologicalnichestomonitordiseaseactivityandtreatmentefficacyinrelapsingmultiplesclerosis
AT hugheskevinr engineeredimmunologicalnichestomonitordiseaseactivityandtreatmentefficacyinrelapsingmultiplesclerosis
AT oakesroberts engineeredimmunologicalnichestomonitordiseaseactivityandtreatmentefficacyinrelapsingmultiplesclerosis
AT caimichellem engineeredimmunologicalnichestomonitordiseaseactivityandtreatmentefficacyinrelapsingmultiplesclerosis
AT millerstephend engineeredimmunologicalnichestomonitordiseaseactivityandtreatmentefficacyinrelapsingmultiplesclerosis
AT iranidavidn engineeredimmunologicalnichestomonitordiseaseactivityandtreatmentefficacyinrelapsingmultiplesclerosis
AT shealonnied engineeredimmunologicalnichestomonitordiseaseactivityandtreatmentefficacyinrelapsingmultiplesclerosis